AIDS Dementia Complex (ADC) represents one of the most severe, clinically devastating neurocognitive manifestations of human immunodeficiency virus type 1 (HIV-1) infection, characterized by progressive cognitive deterioration, behavioral abnormalities, and motor dysfunction. Emerging primarily in the advanced stages of immunosuppression, this syndrome reflects deep subcortical brain pathology precipitated by retroviral neuroinvasion, macrophage activation, and downstream neurotoxicity. Understanding ADC remains paramount in neuropsychiatry and behavioral neurology, both as a historical milestone in neurovirology and as a vital differential in modern neurocognitive management.
AIDS Dementia Complex (ADC)
1. Concise Definition
AIDS Dementia Complex (ADC) is a progressive metabolic encephalopathy induced by human immunodeficiency virus infection, characterized by a triad of cognitive slowing, behavioral disturbances, and motor impairment. Clinically recognized as a subcortical dementia, it arises from indirect neuronal damage mediated by infected brain macrophages and microglia rather than direct infection of neurons themselves.
In modern clinical terminology, ADC corresponds to the most severe category within the broader nosological framework of HIV-associated neurocognitive disorders (HAND), specifically categorized as HIV-Associated Dementia (HAD). The disorder typically manifests when systemic immunocompetence declines significantly, predominantly affecting executive control, mental processing speed, psychomotor agility, and sustained attention.
Although the widespread implementation of combination antiretroviral therapy (cART) has substantially lowered the incidence of full-blown ADC, milder or atypical expressions persist, making the study of its classical presentation essential for differential diagnosis, neuropathological inquiry, and longitudinal patient management.
2. Etymology & Linguistic Origin
The term “AIDS Dementia Complex” was coined in the mid-1980s during the early peak of the acquired immunodeficiency syndrome pandemic. The initialism “AIDS” derives from “Acquired Immune Deficiency Syndrome” (coined in 1982 by the United States Centers for Disease Control and Prevention), referencing an immunopathological state not inherited but acquired through exogenous retroviral infection.
The constituent term “Dementia” originates from the Latin dementia, composed of the privative prefix de- (meaning “out of” or “away from”) and the root mens (genitive mentis, meaning “mind” or “intellect”), paired with the abstract noun suffix -ia. Historically, the term denoted madness or being out of one’s mind, evolving across eighteenth- and nineteenth-century psychiatry into a diagnostic category signifying an acquired, persistent decrement in intellectual and cognitive faculties.
The qualifier “Complex” entered the nosology to acknowledge that the disease was not merely a cognitive ailment, but a multifaceted neurological and behavioral syndrome spanning motor, emotional, and autonomic domains. Neurologists Richard W. Price and Bradford A. Navia introduced the full compound phrase in seminal publications in 1986 to distinguish this specific retroviral encephalopathy from secondary opportunistic central nervous system infections such as cerebral toxoplasmosis or cryptococcal meningitis.
3. Pronunciation & Grammatical Form
The term is pronounced phonetically as an acronym or initialism: /ˌeɪ.diːˈsiː/ (ay-dee-see) when abbreviated, or as the full noun phrase /eɪdz dɪˈmɛn.ʃə ˈkɒm.plɛks/ (AIDS de-MEN-shuh COM-pleks). Grammatically, it functions as a compound proper noun phrase in medical and psychological texts. The plural form, seldom required when referring to the clinical entity, is “AIDS dementia complexes,” though reference is almost universally made to “cases of AIDS dementia complex” or “presentations of ADC.”
Adjectivally, clinicians and researchers frequently employ the terms “ADC-related” or refer to patients as “presenting with ADC-like symptoms.” In contemporary academic manuscripts, the abbreviation HAD (HIV-Associated Dementia) often interchanges with ADC, though ADC remains widely recognized as the classic descriptor for the triad of profound cognitive, motor, and affective decline seen in untreated retroviral illness.
4. Detailed Conceptual Explanation
AIDS Dementia Complex occupies a unique position in behavioral neurology because it fundamentally represents an indirect neurodegenerative disease driven by chronic viral infection of non-neuronal cellular substrates. The primary target cells of HIV-1 within the central nervous system are not neurons or macroglia, but cells of the monocyte-macrophage lineage, specifically perivascular macrophages and parenchymal microglia. Upon traversing the blood-brain barrier via the “Trojan horse” mechanism within migrating monocytes, the virus initiates replication within these resident immune cells.
The subsequent neurocognitive decline seen in ADC is mediated by a persistent neuroinflammatory cascade. Activated, infected macrophages and microglia release high concentrations of neurotoxic viral proteins, including the envelope glycoprotein gp120, the transactivator protein Tat, and the auxiliary regulatory protein Vpr. These viral shedding products, combined with elevated concentrations of host-derived inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), and interleukin-6 (IL-6), trigger severe cellular stress. This milieu stimulates excessive extracellular release of glutamate and inhibits astrocytic glutamate reuptake, culminating in sustained N-methyl-D-aspartate (NMDA) receptor overactivation, excitotoxicity, intracellular calcium influx, oxidative damage, and eventual dendritic pruning and apoptosis of uninfected neurons.
Anatomically, ADC selectively impacts subcortical nuclei and deep white matter. The basal ganglia—specifically the caudate nucleus, putamen, and globus pallidus—bear the highest burden of microglial activation and viral burden, followed by the thalamus, substantia nigra, and deep frontal white matter pathways. Because these subcortical circuits form the structural basis of the frontostriatal loops regulating executive functioning, processing speed, and motor coordination, their disruption results in the hallmark “subcortical dementia” pattern.
Unlike cortical dementias such as classic Alzheimer’s disease, where early disease stages exhibit severe cortical deficits including aphasia, apraxia, and agnosia, individuals with ADC retain fluent speech and primary recognition skills until the final stages. Instead, ADC manifests as profound bradyphrenia (cognitive slowing), impaired concentration, executive dysfunction, emotional apathy, and motor slowing. The clinical landscape is characterized by a patient who can answer questions correctly if provided adequate time, but who struggles with cognitive switching, sustained effort, and physical coordination.
5. Historical Development
The history of AIDS Dementia Complex closely mirrors the evolution of the global HIV/AIDS epidemic and the development of neurovirology as a discipline. In the early 1980s, physicians managing the first cohorts of patients with severe immunodeficiency noted that a substantial proportion developed unexpected, profound changes in mental status, apathy, and motor instability prior to death. Initially, these manifestations were broadly attributed to profound psychological shock, clinical depression, or occult opportunistic infections such as cytomegalovirus encephalitis or fungal meningitis.
A turning point occurred in 1986 when Bradford A. Navia, Barry D. Jordan, and Richard W. Price published landmark papers in the Annals of Neurology. They characterized the unique clinical, radiologic, and pathological hallmarks of the syndrome and formally coined the designation “AIDS Dementia Complex.” Their post-mortem examinations revealed that brain tissue harbored multinucleated giant cells, microglial nodules, and diffuse white matter pallor without evidence of typical opportunistic agents, establishing that HIV-1 exerted a direct or indirect neuropathic effect on the central nervous system.
In 1991, the American Academy of Neurology (AAN) published formalized diagnostic criteria that introduced the terms “HIV-1-Associated Cognitive/Motor Complex,” dividing the syndrome into two primary categories: HIV-1-associated dementia (HAD) for severe impairments and HIV-1-associated minor cognitive/motor disorder (MCMD) for milder manifestations. To operationalize severity, Price and Brew formulated the Memorial Sloan Kettering (MSK) Clinical Staging Scale for ADC, which categorized progression from Stage 0 (normal) through Stage 4 (end-stage mutism and paraplegia).
The landscape transformed dramatically following the introduction of combination antiretroviral therapy (cART) at the 1996 International AIDS Conference in Vancouver. Protease inhibitors and non-nucleoside reverse transcriptase inhibitors dramatically suppressed plasma and cerebrospinal fluid (CSF) viral loads, leading to an immediate, steep decline in the incidence of fulminant ADC. However, as individuals with HIV survived into older adulthood, subtle neurocognitive deficits emerged with high prevalence. In 2007, an international consensus group met in Italy and published the Frascati criteria, which superseded the older AAN framework by dividing HAND into asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-associated dementia (HAD), with the latter preserving the clinical essence of classical ADC.
6. Theoretical Foundations
The conceptual framework underpinning ADC integrates neurovirology, neuroimmunology, and behavioral neurology. Central to this theoretical model is the distinction between direct viral cytotoxicity and bystander neurotoxicity. Because retroviruses do not readily replicate within mature post-mitotic neurons due to the absence of the CD4 receptor and CCR5/CXCR4 coreceptors on neuronal membranes, early researchers wrestled with how extensive neuronal death could occur. The resolution came via the “bystander hypothesis,” which posits that the neuron is an innocent bystander damaged by toxic factors synthesized and released by neighboring infected and activated monocytic cells.
Complementing the bystander model is the frontostriatal disconnection hypothesis. This behavioral neurology model emphasizes that complex cognitive tasks require continuous bidirectional communication between the prefrontal cortex and the subcortical basal ganglia. When retroviral neuroinflammation damages the striatum and white matter tracts, the frontostriatal loop is functionally severed. This models how subcortical structural damage translates into phenotypic executive dysfunction, emotional apathy, and bradyphrenia without overt cortical tissue destruction in the early stages.
Another relevant paradigm is the CNS reservoir theory. The brain represents an anatomically privileged sanctuary site protected by the blood-brain barrier. Many early antiretroviral agents achieved poor penetration across this barrier, creating a sanctuary where viral replication and low-grade inflammation could persist independently of peripheral plasma viral suppression. This concept paved the way for the Central Nervous System Penetration-Effectiveness (CPE) score, which ranks therapeutic regimens by their capacity to access the brain parenchyma and mitigate persistent neuroinflammation.
7. Key Components, Types & Dimensions
The presentation of AIDS Dementia Complex spans three primary symptomatic dimensions, classically referred to as the ADC clinical triad:
- Cognitive Dimension: Characterized by pronounced mental slowing (bradyphrenia), impaired working memory, difficulty with multi-step tasks, reduced attention span, and deficits in executive functions such as abstract reasoning and task switching. Cortical faculties such as vocabulary, semantic knowledge, and basic syntax remain relatively preserved.
- Motor Dimension: Manifests as progressive psychomotor slowing, loss of fine motor coordination, gait instability, and hyperreflexia. Patients frequently exhibit micrographia (small handwriting), clumsy rapid alternating movements, tremor, saccadic smooth pursuit abnormalities, and in late stages, severe spastic paraplegia and quadriparesis.
- Behavioral and Affective Dimension: Dominated by apathy, social withdrawal, loss of initiative, blunted affect, and emotional indifference. A subset of patients may experience paradoxical psychiatric manifestations, including manic psychosis, agitation, severe disinhibition, hallucinations, or organic delusional states.
In clinical practice, staging is commonly structured around the Memorial Sloan Kettering (MSK) staging system:
- Stage 0 (Normal): Cognitive and motor function are fully preserved.
- Stage 0.5 (Subclinical / Equivocal): Minimal or questionable symptoms; mild slowing on neuropsychological testing without functional disability.
- Stage 1 (Mild): Clear cognitive or motor impairment; patient is fully functional in basic activities of daily living (ADLs) but exhibits difficulties with demanding instrumental tasks.
- Stage 2 (Moderate): Inability to perform demanding occupational or instrumental tasks; patient can navigate basic daily needs (eating, dressing) with assistance, but requires supervision; ambulation may require support.
- Stage 3 (Severe): Severe intellectual disability; profound cognitive slowing; inability to follow complex instructions; motor skills deteriorate to profound weakness, requiring a wheelchair or constant assistance.
- Stage 4 (End-Stage): Vegetative state; mute, bedridden, incontinent, with minimal verbal or environmental responsiveness.
8. Examples & Illustrative Cases
To contextualize the trajectory of ADC, consider the historical case of a 38-year-old male diagnosed with HIV-1 prior to the advent of modern combination therapy. Initially presenting with complaints of fatigue and poor work performance as an accountant, his family noted that he had become emotionally detached, rarely speaking unless directly prompted. Routine physical examination appeared normal, but formal testing revealed significant slowing of rapid finger movements, an impaired ability to complete serial subtractions, and difficulty switching categories on card-sorting tasks. Within four months, his handwriting deteriorated into jagged, illegible scrawl, his gait became wide-based and uncoordinated, and he was fired from his job due to gross computational errors. Without therapeutic intervention, his condition deteriorated over ten months into profound mutism, severe generalized hypertonia, and incontinence, ending in death from aspiration pneumonia.
In contrast, a contemporary clinical vignette reflects the subtle, chronic interplay of treated disease: A 56-year-old female with a long history of HIV infection, whose peripheral CD4+ count is maintained at 450 cells/mm³ with an undetectable plasma viral load on stable cART, presents with insidious forgetfulness and declining executive function. Neuropsychological evaluation demonstrates marked processing speed deficits and impaired verbal retrieval, while neuroimaging reveals confluent, symmetric periventricular white matter hyperintensities and prominent basal ganglia atrophy on magnetic resonance imaging (MRI). While not exhibiting the acute, fatal trajectory of classical 1980s ADC, she meets the Frascati criteria for moderate HIV-associated dementia, illustrating the modern persistent manifestation of chronic CNS viral exposure and microglial senescence.
9. Measurement & Assessment
Diagnosing and measuring AIDS Dementia Complex involves a multimodal, exclusionary clinical protocol. Because ADC lacks an isolated pathognomonic biomarker, diagnosis requires establishing the presence of characteristic neurocognitive deficits, demonstrating their association with HIV infection, and systematically ruling out other etiologies.
Neuropsychological assessment represents the cornerstone of functional evaluation. A comprehensive battery must assess at least five distinct cognitive domains, with particular emphasis on frontostriatal performance:
- Information Processing Speed: Evaluated using the Symbol Digit Modalities Test (SDMT) or the Trail Making Test Part A.
- Executive Function: Assessed via the Wisconsin Card Sorting Test (WCST), the Trail Making Test Part B, or the Stroop Color and Word Test.
- Motor Function: Quantified via the Grooved Pegboard Test or finger-tapping tasks to gauge fine motor coordination and psychomotor agility.
- Attention and Working Memory: Measured through the Digit Span forward and backward, and Paced Auditory Serial Addition Test (PASAT).
- Learning and Memory: Assessed through the California Verbal Learning Test (CVLT) or Hopkins Verbal Learning Test-Revised (HVLT-R), evaluating retrieval efficiency versus true storage consolidation deficits.
For rapid bedside screening, clinicians widely utilize the International HIV Dementia Scale (IHDS). The IHDS tests motor speed (timed finger tapping), psychomotor speed (timed alternating hand sequences), and memory-recall tasks, providing a standardized score out of 12 points where a score of 10 or below triggers comprehensive evaluation.
Neuroimaging serves to corroborate clinical impressions and exclude mass lesions. Structural magnetic resonance imaging (MRI) typically demonstrates diffuse cerebral atrophy out of proportion to chronological age, ventricular enlargement (hydrocephalus ex vacuo), and bilateral, symmetric hyperintensities in the periventricular white matter and basal ganglia on T2-weighted and Fluid-Attenuated Inversion Recovery (FLAIR) sequences, without focal mass effect or contrast enhancement. Magnetic resonance spectroscopy (MRS) typically shows decreased N-acetylaspartate (NAA), indicating neuronal loss, paired with elevated myo-inositol and choline peaks, reflecting glial activation and cell membrane turnover.
Cerebrospinal fluid (CSF) analysis is necessary to exclude central nervous system infections (such as progressive multifocal leukoencephalopathy, fungal meningitis, neurosyphilis, and cytomegalovirus). While CSF HIV-1 RNA levels often correlate with ADC severity in untreated individuals, patients with suppressed plasma viral loads can occasionally exhibit “viral escape,” where viral replication persists specifically within the intrathecal compartment.
10. Applications & Practical Significance
The clinical and systemic management of ADC carries substantial practical significance across neuropsychiatry, infectious disease, public health, and rehabilitation disciplines.
In clinical infectious disease and pharmacology, the presence of ADC guides therapeutic selection. Regimens are tailored using the CNS Penetration-Effectiveness (CPE) ranking system. Antiretrovirals with high central nervous system bio-distribution—such as zidovudine, abacavir, emtricitabine, efavirenz, dolutegravir, and darunavir—are prioritized to ensure sustained suppression of viral replication within brain tissue, which can arrest or partially reverse neurological deterioration.
In neuropsychiatry, differentiating ADC from secondary major depressive disorder, apathy syndrome, and delirium is essential. Antidepressants alone fail to resolve the underlying cognitive apathy of ADC, and psychostimulants (e.g., methylphenidate) are sometimes judiciously utilized as adjunctive therapy to alleviate profound psychomotor slowing and executive inertia. Clinicians must maintain heightened vigilance regarding neuroleptic sensitivity; patients with basal ganglia involvement secondary to ADC are extraordinarily susceptible to severe extrapyramidal side effects and neuroleptic malignant syndrome when exposed to dopamine-blocking neuroleptics.
In rehabilitation, occupational and physical therapies are customized to compensate for subcortical decline. Environmental modifications, structured day-planning software, external memory cues, and physical fall-prevention training help preserve autonomy and delay institutionalization for individuals with chronic motor and cognitive slowing.
11. Research & Empirical Evidence
Extensive neurobiological and clinical research has documented the pathogenesis, epidemiology, and treatment response of AIDS Dementia Complex over the past four decades.
Pioneering prospective studies conducted by the Multicenter AIDS Cohort Study (MACS), initiated in the mid-1980s, established that in the pre-cART era, roughly 15% to 30% of individuals with advanced HIV infection developed ADC prior to death. These studies confirmed that a CD4+ T-lymphocyte count falling below 200 cells/mm³ was the strongest systemic predictor of disease onset. Neuropathological investigations by Budka and colleagues (1991) confirmed that the structural correlate of ADC was HIV encephalitis, characterized by multinucleated giant cells, astrogliosis, and myelin pallor.
Following the widespread introduction of combination antiretroviral therapy, studies documented a dramatic drop in incidence. The landmark research by Sacktor and colleagues (2001) showed an over 50% reduction in the incidence of full-blown HIV-associated dementia following the advent of cART. However, subsequent findings from the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study, directed by Igor Grant and published in 2010, revealed a paradox: while severe ADC/HAD declined to less than 2-5% of treated cohorts, the overall prevalence of mild to moderate neurocognitive disorders (ANI and MND) remained high, affecting up to 50% of the ambulatory population despite systemic viral suppression.
Recent neuroimaging research utilizing diffusion tensor imaging (DTI) and functional MRI (fMRI) has corroborated that chronic subclinical white matter damage persists even in virologically suppressed cohorts. Studies demonstrate sustained reductions in fractional anisotropy within the corpus callosum and superior longitudinal fasciculus, confirming ongoing low-level microstructural disruption and chronic neuroinflammation, likely fueled by cellular aging, vascular comorbidities, and latent retroviral reservoirs.
12. Cultural & Cross-Cultural Considerations
The assessment and global burden of ADC are deeply entangled with cultural, socioeconomic, and global health disparities. The vast majority of people living with HIV reside in low- and middle-income countries, particularly across sub-Saharan Africa. In these regions, diagnostic resources such as structural MRI scanners, lumbar puncture facilities, and specialized neuropsychologists are scarce, leading to frequent underdiagnosis or misattribution of ADC symptoms to somatic illness, exhaustion, or psychological stress.
Neuropsychological assessment tools developed in Western, educated, industrialized populations are frequently confounded by cultural and linguistic bias. Standardized tools that measure processing speed through reading or drawing (e.g., the Trail Making Test or Symbol Digit Modalities Test) are disproportionately affected by basic literacy, formal schooling, and familiarity with test-taking conventions rather than true brain injury. Cross-cultural research initiatives led by organizations like the World Health Organization (WHO) have focused on standardizing culturally neutral cognitive batteries, such as the International HIV Dementia Scale (IHDS), which emphasizes motor and non-verbal processing tasks to overcome educational biases.
Stigma remains a pervasive factor affecting the clinical presentation and management of ADC across varied sociocultural contexts. In many societies, cognitive decline and psychiatric alterations linked with retroviral infection invoke intense social ostracism, which delays medical presentation until late-stage physical dependency manifests. Moreover, cultural differences in family structures influence caregiving dynamics: while Western paradigms often default to institutional assisted living, non-Western settings largely rely on extended family structures, underscoring the need for culturally adapted community education programs that explain the organic neurological nature of the patient’s apathy and behavioral changes.
13. Criticisms, Debates & Limitations
The conceptual framework of AIDS Dementia Complex and its broader diagnostic umbrella, HAND, has been the subject of ongoing scientific controversy.
A major debate centers on the validity of the 2007 Frascati criteria, particularly the inclusion of “Asymptomatic Neurocognitive Impairment” (ANI). Critics, including prominent neuropsychologists, argue that defining cognitive impairment as performance falling 1.0 standard deviation below normative data across two cognitive domains creates an unacceptably high rate of false positives. Statistical modeling demonstrates that when administering broad neuropsychological batteries with numerous subtests, up to 15-20% of completely healthy individuals will score 1.0 SD below the mean on at least two measures purely by statistical chance. Skeptics suggest that over-categorizing asymptomatic patients as having a neurological disorder causes unnecessary anxiety, stigmatization, and unneeded modifications to pharmacotherapy.
Another continuous debate focuses on whether ongoing neurocognitive decline in patients with virologically suppressed HIV represents a progressive active neurodegenerative disease or a static historical scar. Proponents of the “legacy effect” hypothesis contend that deficits observed in individuals on long-term cART represent non-progressive neuronal damage sustained during the initial period of profound immunocompromise prior to treatment initiation. In contrast, other investigators argue that neurodegeneration continues slowly over decades, driven by microglial activation, vascular remodeling, and accelerated central nervous system senescence.
Finally, the relative clinical impact of the CNS Penetration-Effectiveness (CPE) score remains contentious. While several retrospective studies associated higher CPE scores with lower CSF viral loads and improved neurocognitive outcomes, other large-scale clinical trials have found no correlation between high CPE regimens and cognitive recovery, with some drugs harboring high CPE scores exhibiting intrinsic neurotoxic properties that could paradoxically aggravate cognitive dysfunction.
14. Related Terms & Distinctions
To ensure diagnostic clarity, AIDS Dementia Complex must be differentiated from several related neurological, psychiatric, and cognitive conditions:
- HIV-Associated Neurocognitive Disorders (HAND): The contemporary overarching umbrella term covering the entire spectrum of retroviral cognitive impairment, of which ADC (specifically HAD) represents the most severe manifestation.
- HIV-Associated Dementia (HAD): The modern diagnostic equivalent of ADC under the Frascati system, defined by significant neurocognitive deficits (at least 2 SD below norms in multiple domains) producing marked functional impairment in basic activities of daily living.
- Mild Neurocognitive Disorder (MND): A intermediate HAND category involving mild functional limitations in daily life, falling between subclinical performance drops and the disabling impairment of ADC.
- Alzheimer’s Disease (AD): A predominantly cortical neurodegenerative dementia characterized primarily by profound early episodic memory loss (rapid forgetting), anomia, and disorientation, contrasting with the subcortical preservation of recognition memory and prominent psychomotor slowing characteristic of ADC.
- Progressive Multifocal Leukoencephalopathy (PML): An opportunistic demyelinating CNS infection caused by the reactivation of the JC virus in immunocompromised patients, presenting with focal neurological deficits (hemiparesis, visual field cuts, aphasia) and asymmetric, non-enhancing white matter lesions on MRI, whereas ADC presents with diffuse, symmetric pathology and global subcortical slowing.
- Major Depressive Disorder (Pseudodementia): A psychiatric affective disorder characterized by dysphoria, suicidal ideation, and negative self-appraisal, whereas ADC is dominated by affective apathy, emotional blunting, and measurable organic motor deficits such as bradykinesia and hyperreflexia.
15. Summary / Key Takeaways
AIDS Dementia Complex (ADC) is a historical and clinical milestone in understanding viral neuropathology. It stands as a profound subcortical dementia syndrome caused by chronic HIV-1 infection of perivascular macrophages and microglia within the central nervous system, which subsequently initiates an inflammatory and excitotoxic cascade that damages frontostriatal pathways.
Clinically, the disorder manifests through a distinct triad of symptoms: cognitive slowing (bradyphrenia and executive dysfunction), motor impairments (gait instability, fine-motor clumsiness, and hyperreflexia), and behavioral alterations (apathy, emotional blunting, and social withdrawal). While the advent of combination antiretroviral therapy (cART) has transformed severe, fatal ADC into a rare presentation in modern clinical practice, milder and chronic variants of HIV-associated neurocognitive disorders remain prevalent, requiring attentive multimodal evaluation, standardized neuropsychological testing, and optimized therapeutic regimens.
References
- Antinori, A., Arendt, G., Becker, J. T., Brew, B. J., Byrd, D. A., Cherner, M., Clifford, D. B., Morgello, S., & Grant, I. (2007). Updated research nosology for HIV-associated neurocognitive disorders. Neurology, 69(18), 1789–1799. https://doi.org/10.1212/01.WNL.0000287431.88658.8b
- Heaton, R. K., Clifford, D. B., Franklin, D. R., Woods, S. P., Ake, C., Vaida, F., Ellis, R. J., Letendre, S. L., Marcotte, T. D., Atkinson, J. H., Rivera Mindt, M., Vigil, O. R., Taylor, M. J., Collier, A. C., Marra, C. M., Gelman, B. B., McArthur, J. C., Morgello, S., Simpson, D. M., … Grant, I. (2010). HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology, 75(23), 2087–2096. https://doi.org/10.1212/WNL.0b013e318200d727
- Navia, B. A., Jordan, B. D., & Price, R. W. (1986). The AIDS dementia complex: I. Clinical features. Annals of Neurology, 19(6), 517–524. https://doi.org/10.1002/ana.410190602
- Price, R. W., & Brew, B. J. (1988). The AIDS dementia complex. The Journal of Infectious Diseases, 158(5), 1079–1084. https://doi.org/10.1093/infdis/158.5.1079
- Sacktor, N. C., Lyles, R. H., Skolasky, R., Anderson, D. E., McArthur, J. C., McFarlane, G., Selnes, O. A., Becker, J. T., Cohen, B., Miller, E. N., & Visscher, B. R. (2001). Combination antiretroviral therapy improves cognitive function in HIV+ individuals: The Multicenter AIDS Cohort Study. Neurology, 56(2), 257–260. https://doi.org/10.1212/wnl.56.2.257